



Biotech Daily

Tuesday June 30, 2015

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: VIRALYTICS UP 22%; ANALYTICA DOWN 8%**
- * **AUSBIOTECH LAUNCHES MEDTECH DIRECTORY IN CHINA**
- * **CLARIFICATION: SPINIFEX, UNISEED**
- * **SUN EGM VOTES TO ACQUIRE DIMERIX, RAISE FUNDS - UNOPPOSED**
- * **NUSEP \$221k LOAN, PRIME UPDATE, CHAIR ALISON COUTTS ON \$269k**
- * **PRIMA 580m WARRANTS, 123m SHARES, 20m CEO RIGHTS, NOTES EGM**
- * **UBS AG BUYS, SELLS, BORROWS IDT SHARES TO 6%**

MARKET REPORT

The Australian stock market recovered 0.67 percent on Tuesday June 30, 2015 with the S&P ASX 200 up 36.5 points to 5,459.0 points.

Fifteen of the Biotech Daily Top 40 stocks were up, 13 fell, 10 traded unchanged and two were untraded. All three Big Caps were up.

Viralytics was the best, up 13.5 cents or 21.6 percent to 76 cents, with 686,805 shares traded, followed by Cellmid up 11.1 percent to three cents with 4.2 million shares traded.

Acrux, Actinogen, Atcor and Oncosil climbed more than five percent; Biotron, Living Cell, Nanosonics and Starpharma rose more than four percent; Compumedics was up 3.85 percent; Admedus, Anteo, Cochlear, Neuren and Resmed were up one percent or more; with CSL and Sirtex up by less than one percent.

Analytica led the falls, down 0.1 cents or 8.3 percent to 1.1 cents with 1.1 million shares traded, followed by Tissue Therapies down 8.1 percent to 3.4 cents with 527,187 shares traded.

Circadian and Prima lost more than five percent; both Avita and Osprey fell four percent; Clinuvel, Genetic Technologies and Reva were down more than three percent; Benitec and Medical Developments shed more than two percent; with Impedimed and Mesoblast down by less than one percent.

AUSBIOTECH

Ausbiotech says it has launched its 'Directory of Australian Medtech Companies' to support small to medium-sized companies seeking to engage with and in China.

Ausbiotech said that 50 Australian diagnostic and device companies are included in the Directory, developed in simplified Chinese and English by Ausbiotech as part of its industry development work to support companies and promote them in China to potential partners and investors.

The industry organization said that the online Directory would be supported by China distribution partner China Bluesky Partners and distributed to Chinese companies and organisations via industry bodies and Government departments in Beijing, Shanghai, Nanjing and Hong Kong.

Ausbiotech said the Directory included companies developing orthopaedic, neurology and cardiology devices, diagnostics and wound care and hospital suppliers.

Ausbiotech said that the Australian medical technology industry had an estimated 500 to 800 companies that are seeking opportunities in global markets and were increasingly seeking support to enter Asian markets, specifically China.

The industry organization said that most of the companies were micro or small enterprises with a turnover of less than \$2 million, with limited capability to assess overseas markets independently.

Ausbiotech said that the Directory would support its 'Medical diagnostics and devices to China' project to promote engagement between Australian medical technologies companies and stakeholders in China.

The industry organization said that both projects had funding support from the Australian Trade Commission, under the Asian Business Engagement grants scheme to support trade between China and Australia in medical technology.

The Directory is at: <http://www.ausmedtechdirectory.org.au>.

SPINIFEX PHARMACEUTICALS

Last night's article on the Novartis \$915.9 million Spinifex acquisition for its neuropathic pain technology briefly mentioned Uniseed's investment.

Uniseed is a venture fund combining investment capital from the universities of Melbourne, Queensland and New South Wales, with Australian Super and it was one of the founding investors in Spinifex with GBS Ventures and the then Symbiosis, now Uniquist, and continued to support Spinifex in all the funding rounds.

Uniseed said it was also an investor in Fibrotech which was sold to Shire for more than \$600 million and is a current investor in Hatchtech and other non-biotechnology stocks.

The oversight was made by the sub-editor receiving the notice shortly before deadline while suffering from a Melbourne lurg, possibly a rhinovirus, but with no Relenza.

The sub-editor has been given three days sick-leave without pay.

SUN BIOMEDICAL, DIMERIX BIOSCIENCE

Sun says all conditions for the acquisition of Dimerix have been satisfied, with an extraordinary general meeting supporting all resolutions unopposed.

Sun said the Dimerix acquisition should be completed by July 3, 2015 on the issue of placement and vendor shares, transaction options and corporate advisor options.

In May, Sun said it would acquire Dimerix for 750,000,041 shares and raise \$1.6 million for a phase II trial of DMX200 for diabetic kidney disease (BD: May 13, 2015).

Sun was unchanged at one cent with 5.15 million shares traded.

NUSEP HOLDINGS

Nusep says that director Andrew Goodall has lent the company \$NZ250,000 (\$A221,250) at 10 percent per annum, repayable on receipt of its R&D Tax Incentive.

Nusep said that the funds would be used for its operations.

The company said that according to 67.8 percent Singapore subsidiary Prime Biologics its initial Singapore Health Sciences Authority clinical good manufacturing practice (cGMP) audit found "a number of non-conformances, primarily with the water for injection as well as documentation for quality and batch processing.

Nusep said that "Prime stated that whilst it is difficult and improbable to achieve a cGMP pass on first attempt, the non-conformances are addressable and Prime has enlisted additional regulatory experts, which Prime states significantly increases the probability of a successful second audit" and it expected to lodge an application for another audit within the next three months.

The company said that Prime had received an advance of \$S1,999,890 (\$A1,935,385) from Xeraya against their second investment tranche, which was an acknowledgement of the progress the company had made towards a GMP licence and to fund the additional work.

Last year, Malaysia's Xeraya Capital Labuan and Singapore's JP Asia Prime Capital invested \$S16 million (then \$A13.7 million) in Prime (BD: May 12, 2014).

Today, Nusep said that Prime had received an advance of \$S519,750 from JP Capital, taking Nusep's holding to 67.8 percent but expected to decrease to 55.1 percent when Prime received all funding tranches.

Nusep said it was in negotiations on a corporate transaction for its holding in Prime.

The company said that interim executive chairman Alison Coutts had been appointed permanent executive chairman on a base salary including superannuation of \$268,783 with a short term annual incentive of \$27,500 effective from July 1 2014, subject to performance targets.

Nusep was unchanged at three cents.

PRIMA BIOMED

Prima shareholders will vote on the issue of 20,000,000 conditional rights to chief executive officer Marc Voigt along with 579,921,226 warrants and 123,143,450 shares.

Prima said that Mr Voigt's free conditional rights vest in three tranches exercisable within 36 months of issue.

The company said that shareholders would vote to ratify the issue of 200,000,000 warrants to the vendors of Immutep.

Prima said the resolutions included ratification of the issue of 22,936,950 shares to Bergen Global Opportunity fund at two cents a share; the ratification of the issue to Ridgeback Capital of 100,206,500 shares at an average price of 1.76 cents a share; approve the issue of 379,921,226 warrants to Ridgeback and 13,750,828 convertible notes to Ridgeback.

The meeting will be held at K&L Gates, Level 31, 1 O'Connell Street, Sydney on July 31, 2015 at 11am (AEST).

Prima fell 0.4 cents or six percent to 6.3 cents with 4.6 million shares traded.

IDT AUSTRALIA

The Singapore-based UBS AG and related bodies corporate have become substantial in IDT with 11,799,262 shares or 6.17 percent.

UBS AG said that between April 7 and June 25, 2015, it and Brispot Nominees bought, sold and borrowed shares including under a prime broking agreement with Regal Funds Management as trustee and manager of Atlantic Absolute Return Fund. UBS said it bought 100,000 shares for \$24,000 or 24 cents share and sold 354,581 shares for \$86,624 or an average price of 24.4 cents a share, with 3,506,688 shares borrowed at no cost.

IDT was unchanged at 23 cents.